Diphenoxylate/Atropine (Lomotil) is the Prescription-Only Antimotility Drug Due to Abuse Potential
Diphenoxylate/atropine (Lomotil) is the correct answer—it is classified as a Schedule V controlled substance and requires a prescription because diphenoxylate is chemically related to the narcotic analgesic meperidine (Demerol), giving it potential for abuse at high doses. 1
Why Diphenoxylate/Atropine Requires a Prescription
Diphenoxylate is a weak opioid analogue of meperidine that exhibits codeine-like subjective effects at high doses (100-300 mg/day, equivalent to 40-120 tablets), and prolonged use at these doses can produce opiate withdrawal symptoms. 1
The drug is classified as Schedule V specifically because of this abuse potential, despite being devoid of morphine-like effects at therapeutic antidiarrheal doses. 1
Real-world abuse has been documented, with case series showing patients taking 3-250 tablets daily (median 25 tablets), often initiated to relieve opioid withdrawals or as a cheap substitute opioid. 2
The atropine component was deliberately added to the formulation to discourage abuse by causing unpleasant anticholinergic effects (dry mouth, urinary retention, tachycardia) at supratherapeutic doses. 3, 1
Why the Other Options Are Incorrect
Loperamide (Imodium):
- Available over-the-counter without prescription. 3, 4
- Despite having a chemical structure similar to opioid receptor agonists like diphenoxylate, loperamide has minimal central nervous system effects because it cannot cross the blood-brain barrier and has low oral absorption. 4
- Considered free of abuse potential at therapeutic doses. 4, 5
Metoclopramide (Reglan):
- A prokinetic agent, not an antimotility drug—it actually increases gastrointestinal motility. 6
- Used for nausea and gastroparesis, not diarrhea treatment. 6
- Not related to meperidine or opioids.
Lubiprostone (Amitiza):
- A chloride channel activator used to treat constipation, not diarrhea. 6
- Works by increasing intestinal fluid secretion—the opposite mechanism needed for diarrhea control.
- Not an antimotility agent and has no relation to opioids.
Clinical Context: Why Loperamide is Preferred Over Lomotil
Major gastroenterological societies (American Gastroenterological Association, ESPEN, British Society of Gastroenterology) uniformly recommend loperamide as first-line antimotility therapy because it is more effective than diphenoxylate/atropine and has fewer central nervous system effects. 6, 3, 5
Loperamide has a longer duration of action than diphenoxylate and possesses additional antisecretory mechanisms that are not mediated by opioid receptors, enhancing its therapeutic effectiveness. 3, 4
Diphenoxylate/atropine should be reserved as a third-line option only after loperamide and octreotide have failed, and only after infectious causes of diarrhea have been definitively excluded. 7, 3
Critical Safety Point
Both loperamide and diphenoxylate/atropine are absolutely contraindicated in children under 2 years of age due to risk of respiratory depression, coma, and permanent brain injury. 7, 3, 8
Neither agent should be used in severe dysentery with high fever or bloody stools, as they can prolong pathogen contact time with intestinal mucosa and worsen outcomes. 6, 7, 3